Dr. Yael Margolin

Dr. Margolin has over 35 years of experience as senior manager, CEO and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development and corporate partnerships. Since 2019, Dr. Margolin has served as a board member to several public and private companies in the healthtech industry, including: Point Biopharma Global (Nasdaq: PNT), Scinai Immunotherapeutics (Nasdaq: SCNI), Purple Biotech (Nasdaq: PPBT), Quris AI, MakeSense, Welltech Ventures, Ramot at Tel Aviv University and TAU Ventures by Tel Aviv University. Dr. Margolin is a founder of mentoring@8400, a boutique voluntary mentoring program for young CEOs in Israel. From 2005 to 2019, she served as President, Chief Executive Officer and director of Gamida Cell Ltd. (Nasdaq: GMDA), a clinical stage biopharmaceutical company, leading the company from preclinical development through phase 3 international registration studies. Prior to that, she was Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin holds a BSc in biology and a MSc Cum Laude from the department of microbiology, both from Tel Aviv University in Israel, a Ph.D. from the department of membrane research at the Weitzman Institute of Science in Rehovot, Israel and was a post-doctoral associate at the Yale University School of Medicine.